- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Gastro-oesophageal cancers
- Meeting Date: March 2023
- Public Summary Document (PSD) March 2023 PBAC Meeting - (PDF 431KB)
- Public Summary Document (PSD) March 2023 PBAC Meeting - (Word 80KB)
Nivolumab – March 2023
Nivolumab (gastro-oesophageal cancers): Injection concentrate for I.V. infusion 40 mg in 4 mL, Injection concentrate for I.V. infusion 100 mg in 10 mL; Opdivo®
Last updated
30 June 2023